A bacteriophage targeting drug-resistant Aeromonas caviae and its application in aquaculture
By developing the phage ACP2401001 targeting drug-resistant ACP2401001, the challenges brought about by the resistance of ACP2401001 of guinea pigs in aquaculture were solved, and efficient inhibition and prevention and control effects were achieved, providing green and safe for aquaculture. biological antibacterial solutions.
Patent Information
- Application Number
- CN202410342891.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-03-25
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2044-03-25
AI Technical Summary
The resistance of Aeromonas guinea pigs in aquaculture has resulted in limited efficacy of traditional antibiotic treatments and has caused serious economic losses and health threats to the aquaculture industry.
A phage ACP2401001 targeting drug-resistant Aerobicus guinea pig was developed to prepare antibacterial agents, therapeutic drugs and feed additives through isolation, purification and application in aquaculture to effectively inhibit the spread and infection of Aerobicus guinea pig. .
This phage has a high lysis rate and good environmental tolerance to drug-resistant Aeromonas guinea pigs, which significantly improves the prevention and control and treatment effects of Aeromonas guinea pigs in aquaculture, reduces mortality, and provides green, Safe biological antibacterial solution.
Smart Images

Figure CN118620846B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of microorganisms, in particular to a bacteriophage targeting drug-resistant Aeromonas caviae and application thereof in aquaculture. Background Art
[0002] Aeromonas caviae belongs to the family Aeromonadaceae and the genus Aeromonas, and is a Gram-negative bacterium. Aeromonas caviae can be found in food, drinking water, sewage and environmental water. Aeromonas caviae is a zoonotic pathogen and an important pathogen in aquatic products, which can easily cause infection complications in hosts with normal or low immunity. Aeromonas caviae can infect a variety of aquatic animals. With the increasing scale and density of aquaculture in my country, the rapid development of aquaculture, unscientific operation, insufficient attention to disease problems, and uneven aquaculture technology levels have inevitably led to more serious aquatic disease problems, causing huge economic losses to farmers and a serious impact on the stable development of the industry.
[0003] Bacterial resistance has always been an important issue in the field of global public health. With the widespread use and abuse of antibiotics, the problem of bacterial resistance has become increasingly prominent, which has had a serious impact on human health and medical systems worldwide. According to literature reports, a sample of Aeromonas caviae isolated from red crucian carp was resistant to erythromycin, tetracycline, neomycin, ampicillin and ciprofloxacin (Zhang Jian et al., 2023); another sample of Aeromonas caviae isolated from Macrobrachium rosenbergii was resistant to tetracycline, ciprofloxacin, norfloxacin, acetylspiramycin, carbenicillin, penicillin, cephalothin, erythromycin, polymyxin and rifampicin (Wang Yuchen et al., 2023).
[0004] At present, the prevention and control of Aeromonas in aquaculture is mainly treated with antibiotics and vaccines (such as Aeromonas hydrophila vaccine), but the efficacy has certain limitations. Therefore, it is necessary to develop a green, safe, and targeted antibacterial phage product for guinea pig Aeromonas; based on this, the present invention provides a phage for drug-resistant guinea pig Aeromonas and its application in aquaculture. Summary of the invention
[0005] In order to prevent aquaculture problems caused by Aeromonas caviae and reduce the mortality caused by the problem, one of the objects of the present invention is to provide a bacteriophage that inhibits Aeromonas caviae.
[0006] The second object of the present invention is to provide the use of Aeromonas caviae bacteriophage ACP2401001 in the preparation of drugs for treating or preventing diseases caused by Aeromonas caviae and / or drug-resistant Aeromonas caviae infection.
[0007] In order to achieve the above-mentioned purpose, the present invention is implemented through the following technical scheme: a phage against drug-resistant Aeromonas caviae, the classification and name of the phage is Aeromonas caviae phage ACP2401001, the applicant isolated a strain of Aeromonas caviae phage ACP2401001 from the water body in the surrounding sea area of a certain place in Guangdong Province, and the phage was sent to the China Center for Type Culture Collection for preservation on February 26, 2024, and the preservation address is: Wuhan University, Wuhan, China; the preservation number is CCTCC NO: M 2024325.
[0008] Furthermore, it also includes a complex of Aeromonas caviae bacteriophage ACP2401001.
[0009] An application of the bacteriophage or the bacteriophage ACP2401001 compound is used in industries such as aquaculture and environmental disinfection to prepare an antibacterial agent for Aeromonas caviae.
[0010] Furthermore, the invention is also used for preparing medicines for treating or preventing diseases caused by Aeromonas guinea pig infection.
[0011] Furthermore, the invention is also used for preparing feed or feed additive for antagonizing Aeromonas caviae.
[0012] Beneficial effects of the present invention:
[0013] 1. The bacteriophage ACP2401001 targeting drug-resistant Aeromonas caviae has a high lysis rate against drug-resistant Aeromonas caviae. The bacteriophage ACP2401001 is effective in inhibiting different Aeromonas caviae, and has important reference significance for the prevention, control and treatment of Aeromonas caviae in sea cucumber farming or aquaculture in the future.
[0014] 2. The guinea pig Aeromonas phage ACP2401001 has a high fermentation rate. At the optimal infection multiplicity MOI = 1, the titer can reach 6.6×10 after 6 hours of fermentation. 11 PFU / mL; in the industrial fermentation process, the fermentation titer can reach 9.4×10 11 PFU / mL.
[0015] 3. The guinea pig Aeromonas phage ACP2401001 with multivalent lysis spectrum has good environmental tolerance. The titer of the guinea pig Aeromonas phage ACP2401001 does not change significantly by an order of magnitude when treated in the pH range of 4-11 for 2h to 24h. The guinea pig Aeromonas phage ACP2401001 has a long survival time at temperatures of 45°C and below, and there is no significant order of magnitude difference in the phage titer after 16W at 4°C and 25°C. It has good stability at 4-37°C, and at 37°C, the phage titer does not change significantly by an order of magnitude at 4W. BRIEF DESCRIPTION OF THE DRAWINGS
[0016] Figure 1 The plaques are of Aeromonas caviae phage ACP2401001;
[0017] Figure 2 is the titer of Aeromonas caviae phage ACP2401001 under different infection multiplicity conditions;
[0018] Figure 3 The results are the stability test results of Aeromonas caviae bacteriophage ACP2401001 at different pH values;
[0019] Figure 4 The results of the stability test of Aeromonas caviae bacteriophage ACP2401001 at different temperatures are shown;
[0020] Figure 5 Schematic diagram of the fermentation dynamics of Aeromonas caviae phage ACP2401001. DETAILED DESCRIPTION
[0021] In order to make the technical means, creative features, objectives and effects achieved by the present invention easy to understand, the present invention is further explained below in conjunction with specific implementation methods.
[0022] See also Figures 1 to 5 , the present invention provides the following technical solutions:
[0023] Embodiment 1:
[0024] Isolation and Purification of Aeromonas caviae Phage ACP2401001
[0025] Thirty water samples were collected from a certain aquaculture area in Guangdong Province. Each sample was 30 mL and centrifuged at 6000 rpm for 10 min. The supernatant was sterilized with a 0.22 μm filter. 5 mL of the filtrate was mixed with 0.5 mL of Aeromonas caviae (concentration of about 5 × 10 8CFU / mL) were mixed evenly and cultured overnight in a shaker at 37°C at 200 rpm. The fermentation broth was centrifuged at 6000 rpm for 10 min, the supernatant was sterilized with a 0.22 μm filter, and 100 μL of the filtrate was mixed with 300 μL of Aeromonas caviae (concentration of about 1×10 8 CFU / mL) and mix well, add 1% sodium chloride TSB semi-solid (containing 0.65% agar), gently invert and pour evenly on the 1% sodium chloride TSA bottom plate, and after solidification, place the culture dish in a 37°C incubator for overnight culture. Pick up the transparent and bright plaque spots, shake and desorb in 1mL SM liquid, and sterilize through a 0.22μm microporous filter to obtain the phage filtrate, inoculate it in 5mL 1% sodium chloride TSB liquid culture medium, add 500μL of the corresponding host guinea pig Aeromonas bacterial liquid and mix well, shake and culture at 200rpm overnight at 37°C, centrifuge at 6000rpm for 10min, take the supernatant and sterilize through a 0.22μm microporous filter to obtain the phage filtrate, and observe the plaque morphology by the double-layer plate method. After repeating the operation 3-5 times, plaques of uniform shape and size can be obtained.
[0026] A strain of Aeromonas caviae phageACP2401001 was isolated from the water sample. Figure 1 As shown, the plaques formed by it and the host bacteria are transparent, round, and 0.5 mm in diameter. The phage was sent to the China Center for Type Culture Collection on February 26, 2024, and the classification name is: Vibrioparahaemolyticus phage ACP2401001, address: Wuhan University, Wuhan, China, and the collection number is CCTCC NO: M2024325.
[0027] Embodiment 2:
[0028] Determination of the titer of Aeromonas caviae phage ACP2401001 under different infection multiplicity conditions
[0029] The host bacteria of the phage ACP2401001 of the guinea pigs, the phage ACP2401001 of the guinea pigs, the phage ACP2401001, was inoculated into an EP tube with 3 mL of 1% sodium chloride TSB, and cultured at 37°C for 5-8 hours to obtain the ACDC001 bacterial solution. The bacterial solution was inoculated into 100 mL of TSB medium at a 2% inoculation amount, and when ACDC001 grew to the initial logarithmic phase, the phage ACP2401001 was inoculated, and the infection was carried out according to different multiplicity of infection (MOI; MOI = number of phages / number of bacteria, see Figure 2 ), each experiment was performed in triplicate. The cells were cultured in a 37°C shaker at 200 rpm for 12 h.
[0030] Results Figure 2 When MOI = 1, the fermentation titer reached a maximum of 6.6×10 11 PFU / mL.
[0031] Embodiment 3:
[0032] pH Stability Test of Aeromonas caviae Phage ACP2401001
[0033] 1 mL of the fermentation broth of Aeromonas caviae bacteriophage ACP2401001 was added to 9 mL of TSB liquid medium with pH values of 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, 10.0, 11.0, and 12.0, respectively (the titer after dilution was 5 × 10 8 pfu / mL), and placed in a 25°C incubator for incubation for 0h, 2h, and 24h. Samples were taken after adjusting the pH to the original culture medium Ph=7.4 with hydrochloric acid and sodium hydroxide solutions, respectively, and then multiple dilutions were performed. The phage titer was determined by the double-layer plate method; duplicate cultures were performed at each point and the average value was taken, and the experiment was repeated 3 times.
[0034] The results are as follows Figure 3 As shown, the potency of Aeromonas caviae phage ACP2401001 did not change significantly in the order of magnitude when treated with pH in the range of 4-11 for 24 hours.
[0035] Embodiment 4:
[0036] Temperature stability test of Aeromonas caviae bacteriophage ACP2401001
[0037] The fermentation broth of Aeromonas guinea pig bacteriophage ACP2401001 was centrifuged and filtered, and 1 mL was dispensed into 1.5 mL centrifuge tubes (initial titer was 5 × 10 8 pfu / mL). The centrifuge tubes containing phages were placed in a constant temperature of 4, 25, 37, 45, 55, 65, and 75°C for 0h, 1h, 24h, 48h, 92h, 1w, 2w, 4w, 8w, 12w, and 16w. After the action time, the sample tubes were taken out and immediately placed in an ice bath for cooling. After appropriate dilution, the phage titer was determined by the double-layer plate method. Each point was cultured in duplicate to obtain the average value, and the experiment was repeated 3 times.
[0038] The results are as follows Figure 4As shown, the survival time of Aeromonas guinea pig phage ACP2401001 is longer at temperatures of 45°C and below. At 4°C, the phage titer has no obvious order of magnitude difference after 16 weeks, at 25°C, the phage titer has no obvious order of magnitude difference after 8 weeks, and at 37°C, the phage titer has no obvious order of magnitude difference after 4 weeks. It has good stability at 4-37°C and can be effectively preserved.
[0039] Embodiment 5:
[0040] Host range of bacteriophage ACP2401001
[0041] In each experiment, 20 strains of Aeromonas guinea pigs were selected. The selected Aeromonas guinea pigs all contained tetA gene (tetracycline resistance gene) and ermb (macrolide resistance gene). The selected 20 strains of Aeromonas guinea pigs were resistant to tetracycline with a resistance rate of 100%, a resistance rate of 65% to neomycin, and a resistance rate of 85% to ampicillin. The 20 strains of Aeromonas guinea pigs were inoculated in 3mL of 1% sodium chloride TSB EP tubes, and oscillated at 37°C and 200rpm for 8h to obtain Aeromonas guinea pig bacterial liquid. A sufficient amount of TSA bottom plate was prepared, 0.5ml of Aeromonas guinea pig bacterial liquid was mixed evenly with 6mL of 2% sodium chloride TSB semi-solid culture medium (containing 0.65% agar) at about 50°C, and slowly spread on the 1% sodium chloride TSA bottom plate; after the plate culture medium solidified to room temperature, 5×10 8 5 μL of phage ACP2401001 with a concentration of PFU / ml was dropped onto the plate, and after air drying, the plate was inverted and placed in a 37°C constant temperature biochemical incubator for about 8 hours, and the results were observed. Each group of experiments was repeated 3 times.
[0042] As shown in Table 1, the A. guinea pig phage ACP2401001 can lyse 18 of the 20 strains of drug-resistant A. guinea pigs, with a lysis rate of 90%. The experimental results confirm that this phage has a very outstanding effect in inhibiting drug-resistant A. guinea pigs, and has great value for the prevention, control and treatment of A. guinea pigs in the aquaculture industry in the future.
[0043] Table 1 Lysis effect of bacteriophage ACP2401001
[0044]
[0045]
[0046] Note: “-” indicates no lysis, “+” indicates lysis and the plaques are relatively transparent; “++” indicates lysis and the plaques are transparent.
[0047] Embodiment 6:
[0048] Fermentation preparation of Aeromonas caviae bacteriophage ACP2401001
[0049] A single colony of Aeromonas caviae ACGD001 was picked from the plate and inoculated into 3 mL of 1% sodium chloride TSB medium, and cultured at 37°C and 200 rpm for 8 h to obtain the host bacterial solution. The bacterial suspension was inoculated into 120 mL of 1% sodium chloride TSB medium at a 2% inoculum, and cultured at 37°C and 150 rpm until the early logarithmic phase, and the bacterial solution OD600 value was 0.1.
[0050] The industrial fermentation is a 10L fermentation tank, the fermentation system is 6L, the medium used is TSB, the initial pH value is 7.4, the flame method is used to inoculate guinea pig Aeromonas at a 1% inoculation amount, and the phage ACP2401001 is added to the fermentation system at the optimal infection condition MOI=1. Sterile air is introduced during the fermentation process, and 3‰ defoamer is added. The fermentation preparation time is 12h. Since the start of fermentation, 20ml of fermentation liquid is taken from the sampling port in a sterile container at 1h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, 9h, 10h, 11h, and 12h, and centrifuged at 6000rpm for 10min. The supernatant is sterilized through a 0.22μm microporous filter membrane to obtain a filtrate containing phage and its titer is determined. The method is referred to Example 2.
[0051] After the fermentation is completed, the entire mixed solution of phage and host bacteria is taken out from the sampling port and placed in a sterile container, centrifuged at 6000 rpm for 10 min, and the supernatant is filtered through a vacuum pump into a sterile filter device to obtain the phage fermentation solution and stored at 4°C.
[0052] Depend on Figure 5 It can be seen that the titer of Aeromonas guinea pig phage ACP2401001 reached a maximum of 9.4×10 11 PFU / mL, in the period of 6h to 12h, the titer is stable at 10 11 PFU / mL; The results show that it is feasible to use fermentation method for industrial production of bacteriophages, which provides effective reference data for the preparation of bacteriophage products.
[0053] Embodiment 7:
[0054] Experimental study on the prevention of Aeromonas caviae phage ACP2401001 against Aeromonas caviae infection in Litopenaeus vannamei
[0055] The white shrimps in the experiment were provided by a Penaeus vannamei farm in Zhuhai, Guangdong. The selected Penaeus vannamei had a normal and healthy appearance, with an individual size of about 6.5 cm in length and about 80 heads / 500 g. Before the experiment, the Penaeus vannamei were uniformly placed in a 250L aquarium to adapt to breeding for 7 days, with a water pH of 7.3±0.1, a temperature of 25°C, and a dissolved oxygen of 6.6±0.1 mg / L. When the shrimp mortality rate was stabilized within 0% to 2%, the experiment was prepared. The Aeromonas caviae used in this example was ACGD002, and the selected phage was the Aeromonas caviae phage ACP2401001 of the present invention.
[0056] The experimental design is as follows: Penaeus vannamei were divided into 5 groups, with 100 shrimps in each group, and the experiment lasted for 7 days:
[0057] 1) Control group: Each shrimp was injected with an equal volume of saline (injected near the third abdominal segment of the tail fan);
[0058] 2) Challenge group: Each shrimp was injected with a concentration of 1×10 6 100 μL of bacterial solution with CFU / mL.
[0059] 3) Treatment group: Each shrimp was injected with a concentration of 1×10 6 CFU / mL of bacterial solution 100μL; after 6h, inject bacteriophage ACP24010011×10 6 PFU / treatment only;
[0060] 4) Prevention group: 1 day before the experiment, 11×10 6 PFU / each shrimp was injected with 1×10 6 CFU / mL bacterial solution 100μL;
[0061] 5) Tetracycline treatment group: Each shrimp was injected with a final concentration of 1×10 6 CFU / mL of bacterial solution 100μL. After 12h, add tetracycline according to the dosage instructions for treatment;
[0062] 5) Enrofloxacin treatment group: Each shrimp was injected with a final concentration of 1×10 6 CFU / mL of bacterial solution 100 μL. After 12 hours, add enrofloxacin according to the dosage specified for treatment.
[0063] The experiment lasted for 7 days, and the symptoms and number of deaths of Penaeus vannamei were recorded. After the observation period ended, the tissues of Penaeus vannamei in each group were mixed and ground, and the total count of Aeromonas guinea pigs was performed using RS plates (Aeromonas screening plates). The survival rate of Penaeus vannamei was calculated for each group, and the calculation method is as follows.
[0064]
[0065] ATotal: the total number of Penaeus vannamei in each group of the experiment, pieces;
[0066] A Death: The total number of deaths of Penaeus vannamei in each group of the experiment, pieces;
[0067] C: Survival rate of Penaeus vannamei in each group of the experiment, %.
[0068] The experimental results are shown in Table 3. The survival rate of the blank group was 96%, and the survival rate of the vannamei shrimp in the challenge group was 0%; the survival rate of the treatment group was 91%, the survival rate of the prevention group was 93%, the survival rate of the tetracycline group was 24%, and the survival rate of the enrofloxacin group was 88%. The experimental results revealed that the phage ACP2401001 of Aeromonas caviae can effectively kill Aeromonas caviae, and the content of Aeromonas caviae in both the prevention and treatment groups was effectively reduced, and the survival rate of the vannamei shrimp was improved. This example provides an important reference value for the prevention and treatment of Aeromonas caviae in shrimp in the future, and can be used as a biological antibacterial agent for the prevention and treatment of Aeromonas caviae diseases in vannamei shrimp and other aquatic animals.
[0069] Table 2 The control effect of bacteriophage ACP2401001 on Aeromonas caviae in Litopenaeus vannamei
[0070]
[0071]
[0072] This embodiment shows and describes the basic principles and main features of the present invention and the advantages of the present invention. It is obvious to those skilled in the art that the present invention is not limited to the details of the above exemplary embodiments, and the present invention can be implemented in other specific forms without departing from the spirit or basic features of the present invention. Therefore, no matter from which point of view, the embodiments should be regarded as exemplary and non-restrictive. The scope of the present invention is defined by the attached claims rather than the above description, and it is intended that all changes falling within the meaning and scope of the equivalent elements of the claims are included in the present invention. Any figure mark in the claims should not be regarded as limiting the claims involved.
[0073] In addition, it should be understood that although the present specification is described according to implementation modes, not every implementation mode contains only one independent technical solution. This description of the specification is only for the sake of clarity. Those skilled in the art should regard the specification as a whole. The technical solutions in each embodiment may also be appropriately combined to form other implementation modes that can be understood by those skilled in the art.
Claims
1. A bacteriophage against drug-resistant Aeromonas caviae, Features: The classification name of the phage is Aeromonas caviae phage ACP2401001. The applicant isolated a strain of Aeromonas caviae phage ACP2401001 from the waters around a certain place in Guangdong Province. The phage was sent to the China Center for Type Culture Collection for preservation on February 26, 2024. The preservation address is: Wuhan University, Wuhan, China; the preservation number is CCTCC NO: M 2024325.
2. A use of the bacteriophage against drug-resistant Aeromonas caviae as claimed in claim 1, Features: Used in aquaculture and environmental disinfection industries.
3. A use of the bacteriophage against drug-resistant Aeromonas caviae as claimed in claim 1, Features: It is used to prepare antibacterial agents for Aeromonas caviae.
4. A use of the bacteriophage against drug-resistant Aeromonas caviae as claimed in claim 1, Features: The invention is used for preparing medicines for treating or preventing diseases caused by Aeromonas guinea pig infection.
5. A use of the bacteriophage against drug-resistant Aeromonas caviae as claimed in claim 1, Features: The invention is used for preparing feed or feed additive for antagonizing Aeromonas guinea pigs.
